Haloperidol Concentrations in Patients With Alzheimer's Dementia

Maurice W. Dysken; Sue B. Johnson; Lori Holden; Govind Vatassery; Julie Nygren; Mary Jelinski; Michael Kuskowski; Larry Schut; J. Riley McCarten; David Knopman; Gabe J. Maletta; Stacy Skare

doi:10.1097/00019442-199405000-00006

Haloperidol Concentrations in Patients With Alzheimer's Dementia

Maurice W. Dysken, Sue B. Johnson, Lori Holden, Govind Vatassery, Julie Nygren, Mary Jelinski, Michael Kuskowski, Larry Schut, J. Riley McCarten, David Knopman, Gabe J. Maletta, Stacy Skare

Neurology

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

To investigate the relationship between clinical response and haloperidol blood concentrations in Alzheimer's dementia (AD) patients with behavior problems, 29 AD inpatients were assigned to a fixed oral dosage of haloperidol (0.5 mg, 1.0 mg, or 2.0 mg) every 12 hours for 3 weeks. BEHAVE-AD ratings and concentrations of plasma and RBC haloperidol and reduced haloperidol were obtained on Days 8, 15, and 22. Although no significant linear or curvilinear relationships were apparent between percent of change on BEHAVE-AD and plasma or RBC haloperidol concentrations, a good response (change ≥ 30%) was observed in 55% of the patients who entered the study.

Original language	English (US)
Pages (from-to)	124-133
Number of pages	10
Journal	American Journal of Geriatric Psychiatry
Volume	2
Issue number	2
DOIs	https://doi.org/10.1097/00019442-199405000-00006
State	Published - 1994

ASJC Scopus subject areas

Geriatrics and Gerontology
Psychiatry and Mental health

Access to Document

10.1097/00019442-199405000-00006

Cite this

@article{3a07137d02b24d4cae50e20b6d0d658d,

title = "Haloperidol Concentrations in Patients With Alzheimer's Dementia",

abstract = "To investigate the relationship between clinical response and haloperidol blood concentrations in Alzheimer's dementia (AD) patients with behavior problems, 29 AD inpatients were assigned to a fixed oral dosage of haloperidol (0.5 mg, 1.0 mg, or 2.0 mg) every 12 hours for 3 weeks. BEHAVE-AD ratings and concentrations of plasma and RBC haloperidol and reduced haloperidol were obtained on Days 8, 15, and 22. Although no significant linear or curvilinear relationships were apparent between percent of change on BEHAVE-AD and plasma or RBC haloperidol concentrations, a good response (change ≥ 30%) was observed in 55% of the patients who entered the study.",

author = "Dysken, {Maurice W.} and Johnson, {Sue B.} and Lori Holden and Govind Vatassery and Julie Nygren and Mary Jelinski and Michael Kuskowski and Larry Schut and McCarten, {J. Riley} and David Knopman and Maletta, {Gabe J.} and Stacy Skare",

note = "Funding Information: This work was supported by a Merit Review Grant from Department of Veterans Affairs Medical Research. ",

year = "1994",

doi = "10.1097/00019442-199405000-00006",

language = "English (US)",

volume = "2",

pages = "124--133",

journal = "American Journal of Geriatric Psychiatry",

issn = "1064-7481",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Haloperidol Concentrations in Patients With Alzheimer's Dementia

AU - Dysken, Maurice W.

AU - Johnson, Sue B.

AU - Holden, Lori

AU - Vatassery, Govind

AU - Nygren, Julie

AU - Jelinski, Mary

AU - Kuskowski, Michael

AU - Schut, Larry

AU - McCarten, J. Riley

AU - Knopman, David

AU - Maletta, Gabe J.

AU - Skare, Stacy

N1 - Funding Information: This work was supported by a Merit Review Grant from Department of Veterans Affairs Medical Research.

PY - 1994

Y1 - 1994

N2 - To investigate the relationship between clinical response and haloperidol blood concentrations in Alzheimer's dementia (AD) patients with behavior problems, 29 AD inpatients were assigned to a fixed oral dosage of haloperidol (0.5 mg, 1.0 mg, or 2.0 mg) every 12 hours for 3 weeks. BEHAVE-AD ratings and concentrations of plasma and RBC haloperidol and reduced haloperidol were obtained on Days 8, 15, and 22. Although no significant linear or curvilinear relationships were apparent between percent of change on BEHAVE-AD and plasma or RBC haloperidol concentrations, a good response (change ≥ 30%) was observed in 55% of the patients who entered the study.

AB - To investigate the relationship between clinical response and haloperidol blood concentrations in Alzheimer's dementia (AD) patients with behavior problems, 29 AD inpatients were assigned to a fixed oral dosage of haloperidol (0.5 mg, 1.0 mg, or 2.0 mg) every 12 hours for 3 weeks. BEHAVE-AD ratings and concentrations of plasma and RBC haloperidol and reduced haloperidol were obtained on Days 8, 15, and 22. Although no significant linear or curvilinear relationships were apparent between percent of change on BEHAVE-AD and plasma or RBC haloperidol concentrations, a good response (change ≥ 30%) was observed in 55% of the patients who entered the study.

UR - http://www.scopus.com/inward/record.url?scp=0028091617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028091617&partnerID=8YFLogxK

U2 - 10.1097/00019442-199405000-00006

DO - 10.1097/00019442-199405000-00006

M3 - Article

AN - SCOPUS:0028091617

SN - 1064-7481

VL - 2

SP - 124

EP - 133

JO - American Journal of Geriatric Psychiatry

JF - American Journal of Geriatric Psychiatry

IS - 2

ER -

Haloperidol Concentrations in Patients With Alzheimer's Dementia

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this